Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Wilson H. Miller et al.|The Lancet|2012Cited by 3k
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2013Cited by 112
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cellsSylvia Janetzki, Axel Hoos, Leah Price et al.|Cancer Immunology Immunotherapy|2009Cited by 52
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Unknown|2012Cited by 7